Guardant Health, Inc. (NASDAQ:GH) Shares Acquired by National Asset Management Inc.

National Asset Management Inc. lifted its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 59.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,204 shares of the company’s stock after purchasing an additional 5,315 shares during the period. National Asset Management Inc.’s holdings in Guardant Health were worth $1,820,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sandy Spring Bank raised its holdings in Guardant Health by 3,333.3% in the second quarter. Sandy Spring Bank now owns 206 shares of the company’s stock valued at $26,000 after acquiring an additional 200 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in Guardant Health in the first quarter valued at $44,000. Tsfg LLC raised its holdings in Guardant Health by 214.0% in the second quarter. Tsfg LLC now owns 314 shares of the company’s stock valued at $39,000 after acquiring an additional 214 shares in the last quarter. Harbour Investments Inc. acquired a new stake in Guardant Health in the first quarter valued at $61,000. Finally, Cibc World Markets Corp acquired a new stake in Guardant Health in the first quarter valued at $244,000. 87.58% of the stock is currently owned by institutional investors and hedge funds.

Shares of GH opened at $132.05 on Friday. The firm has a 50-day moving average price of $117.02 and a 200 day moving average price of $129.06. The firm has a market capitalization of $13.38 billion, a PE ratio of -35.03 and a beta of 0.51. The company has a quick ratio of 19.30, a current ratio of 19.57 and a debt-to-equity ratio of 1.44. Guardant Health, Inc. has a 52-week low of $96.66 and a 52-week high of $181.07.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, August 5th. The company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.87) by ($0.09). Guardant Health had a negative net margin of 116.99% and a negative return on equity of 37.35%. The business had revenue of $92.10 million for the quarter, compared to the consensus estimate of $84.63 million. On average, equities analysts expect that Guardant Health, Inc. will post -3.98 EPS for the current year.

GH has been the topic of a number of research reports. Wells Fargo & Company increased their target price on shares of Guardant Health from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, June 21st. The Goldman Sachs Group initiated coverage on shares of Guardant Health in a report on Thursday, June 3rd. They set a “buy” rating and a $160.00 target price on the stock. SVB Leerink reissued a “buy” rating on shares of Guardant Health in a report on Sunday, May 23rd. William Blair reissued a “buy” rating on shares of Guardant Health in a report on Thursday, May 27th. Finally, Zacks Investment Research raised shares of Guardant Health from a “sell” rating to a “hold” rating in a report on Monday, August 16th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $164.00.

In other Guardant Health news, Director Ian T. Clark sold 10,559 shares of the company’s stock in a transaction dated Tuesday, June 29th. The shares were sold at an average price of $130.00, for a total transaction of $1,372,670.00. Following the completion of the sale, the director now directly owns 5,719 shares of the company’s stock, valued at $743,470. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Stanley J. Meresman sold 4,934 shares of the stock in a transaction that occurred on Monday, July 12th. The stock was sold at an average price of $124.27, for a total transaction of $613,148.18. Following the completion of the sale, the director now directly owns 8,993 shares of the company’s stock, valued at $1,117,560.11. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,361 shares of company stock valued at $3,190,158. Insiders own 5.80% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.

Further Reading: Euro STOXX 50 Index

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.